Board Composition Strategy When You Only Have Five Seats
Board composition is one of the most consequential governance decisions a biopharma company makes, and it is one of the least deliberate. In too many companies, board seats are filled reactively — an investor takes a seat as a condition of funding, the CEO takes a seat by default, and the remaining seats are filled by people the CEO or lead investor happens to know. The result is a board that reflects the company's fundraising history rather than its governance needs.
This matters in any company. In a clinical-stage biopharma company with five to seven board seats, it matters enormously. There is no room for a director who does not contribute. Every seat that is occupied by someone who lacks relevant expertise or who is present for reasons of politics or obligation is a seat that is unavailable for someone who could make the board more effective at governing through the company's most difficult decisions.
The Expertise Gap Problem
A well-functioning biopharma board needs coverage across at least five areas of expertise: scientific and clinical development, regulatory affairs, financial and capital markets, commercial strategy, and corporate governance. In an ideal world, every board member would bring deep expertise in one area and working knowledge of the others.
In the real world of a five-seat board, the math does not work. Two seats are typically committed before the composition discussion begins — one for the CEO and one for the lead investor. That leaves three seats to cover five areas of expertise. Something has to give.
The most common gap is scientific expertise. This is paradoxical, because the entire enterprise depends on the science. But scientific experts — practicing physicians, academic researchers, experienced drug developers — are often viewed as less essential to the board than financial or governance-oriented directors. The assumption is that management provides the scientific expertise and the board provides the business oversight.
This assumption is dangerous. When the board must make a go/no-go decision on a Phase III trial, when it must evaluate whether to pursue a new indication, when it must assess whether the Chief Medical Officer's interpretation of clinical data is sound — these are moments when the board needs scientific judgment that is independent of management. A board without scientific expertise in these moments is governing blind.
Principles for Composition Strategy
Start with the Company's Stage, Not a Template
The expertise a biopharma board needs changes as the company progresses through its lifecycle. A preclinical company preparing for its first IND filing needs different board expertise than a company midway through Phase III preparing for a potential exit.
At the earliest stages, the board's most critical need is scientific credibility and clinical development expertise. The company is making foundational decisions about which programs to advance, how to design trials, and how to interact with regulators. Directors who understand drug development from a governance perspective — who can ask the right questions without trying to run the science — are essential.
As the company advances into later-stage clinical development, financial and strategic expertise becomes more important. The company is spending significant capital, approaching fundraising milestones, and beginning to attract partnership and acquisition interest. Directors with M&A experience, public markets knowledge, and commercial strategy perspectives become more valuable.
At the exit preparation stage, the board needs directors who have navigated exits — either as board members of acquired companies, as advisors to transactions, or as acquirers themselves. This is specialized knowledge that no amount of general governance experience provides.
The mistake many companies make is building the board for the current stage and never revisiting composition as the company evolves. A board that was perfectly composed for a preclinical company may be inadequately composed for a company entering Phase III.
Distinguish Between Expertise and Representation
Board seats in venture-backed companies often serve a dual function: they provide governance expertise and they represent a shareholder constituency. The lead investor's partner takes a seat to represent the fund's interests. The founder-CEO takes a seat to represent management's perspective. These dual-purpose seats are a reality of the venture model.
The problem arises when representation crowds out expertise. A board where three of five seats are occupied by investor representatives — each of whom has general venture capital experience but none of whom has deep biopharma expertise — is a board that serves its investors well and its company poorly.
The governance discipline is to ensure that investor directors bring genuine relevant expertise, not just capital representation. When negotiating board composition as part of a financing, the company should push for investor directors who have biopharma-specific experience, regulatory knowledge, or scientific backgrounds rather than generalist venture partners who will serve on the board primarily as stewards of their fund's investment.
Value Independent Scientific Expertise
The single most undervalued competency on biopharma boards is independent scientific judgment. Every clinical-stage company faces moments when the board must evaluate scientific information that management has a strong incentive to present favorably. An independent director with genuine scientific or clinical expertise — someone who can read a clinical study report, question a statistical analysis plan, or challenge a regulatory strategy — provides a governance check that no amount of financial or legal expertise can replicate.
This does not mean the board needs a bench scientist. The most effective scientific directors are people who combine scientific training with business judgment — former CMOs, experienced drug development executives, physician-scientists who have moved into the commercial world. They understand the science well enough to ask informed questions and they understand governance well enough to know when questions need to be asked.
Plan for Board Evolution
Board composition should be a recurring agenda item, not a one-time decision. At least annually, the board should evaluate whether its composition still matches the company's needs. As the company approaches major milestones — a Phase III decision, a fundraising round, an exit — the board should assess whether it has the expertise to govern through that milestone effectively.
This evaluation should be honest. It is not comfortable to conclude that a current board member's expertise is no longer what the company needs. But a board that keeps directors whose contributions have diminished rather than making changes to improve governance effectiveness is prioritizing politeness over performance.
In practice, board evolution in venture-backed companies is often driven by financing events. New investors demand seats, and the board expands or existing members rotate off. The governance opportunity is to use these transition moments strategically — to ensure that incoming directors fill expertise gaps rather than simply representing another fund.
The Practical Constraints
Seats as Currency
Board seats in venture-backed biopharma are currency. Investors exchange capital for seats. Advisors accept below-market compensation in exchange for the credential and the equity. CEOs view their board seat as a symbol of authority. This means that board composition decisions are never purely about expertise — they are negotiations with financial and political dimensions.
The best outcome is when the governance interest and the political interest align — when the investor who demands a seat happens to bring the expertise the board needs. This alignment is not accidental. It results from a company that communicates its governance needs clearly during fundraising and pushes for investor directors who add value beyond capital representation.
The Challenge of Diversity
Biopharma boards are among the least diverse governance bodies in corporate America. The pool of people with relevant board experience — biopharma industry experience, clinical development knowledge, fundraising and M&A exposure — is small and historically homogeneous. Expanding this pool is both a governance imperative (diverse boards make better decisions) and a practical challenge (the candidates exist but the networks that surface them are narrow).
Companies serious about board diversity need to look beyond the traditional referral networks — the same venture partners, the same former executives, the same governance consultants who produce the same candidates. Organizations like Boardlist, Him for Her, and various industry-specific networks can surface qualified candidates who would never appear through conventional channels.
Compensation and Commitment
Board service at a clinical-stage biopharma company requires a meaningful time commitment — typically 150 to 250 hours per year, with spikes during periods of intense activity. Compensation is usually equity-based, with cash compensation that is modest relative to public company boards.
This compensation structure affects composition. Directors who need significant cash compensation — because they are between roles, because they serve on many boards, or because their financial situation requires it — may not be attracted to clinical-stage companies. The best candidates are often people who view the equity as meaningful and who are motivated by the intellectual engagement and the opportunity to contribute to bringing a therapy to patients.
Making It Work with Five Seats
The constraint is real. Five seats is not enough to cover every expertise area the company needs. The governance discipline is to prioritize ruthlessly, to ensure that every seat is occupied by someone who contributes meaningfully, and to supplement board expertise with other resources — scientific advisory boards, external consultants, informal advisors — when the board itself cannot cover a critical area.
A five-person board with three deeply engaged, expertly selected directors and two representatives can be highly effective. A seven-person board with seven people who are present for political reasons and contribute nothing of substance is a governance failure regardless of its size.
Board composition is a strategy, not an accident. Treat it with the same rigor you would apply to any other strategic decision the company makes.